Acquisitions and Investments - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands				2 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	May 09, 2022	Apr. 29, 2022	Sep. 14, 2021	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Schedule of Equity Method Investments [Line Items]
Value of consideration shares							$ 172,000	$ 0
Total assets of equity method investees				$ 2,369,602	$ 2,369,602		2,369,602		$ 2,399,715
Total liabilities of equity method investees				650,803	650,803		650,803		714,589
Market value				1,900	1,900		1,900		4,500
Upfront payment received					309,893	$ 442,408	639,111	987,573
Transfer of intellectual property and other
Schedule of Equity Method Investments [Line Items]
Upfront payment received					87,197	$ 9,548	93,159	$ 13,816
LeaderMed | LeaderMed Joint Venture | Corporate Joint Venture
Schedule of Equity Method Investments [Line Items]
Joint venture (in shares)			4,703
Ownership interest in joint venture (as a percent)			47.00%
LeaderMed | LeaderMed Joint Venture | Corporate Joint Venture | Transfer of intellectual property and other
Schedule of Equity Method Investments [Line Items]
Upfront payment received			$ 1,000						1,000
Equity Method Investment, Nonconsolidated Investee or Group of Investees
Schedule of Equity Method Investments [Line Items]
Total assets of equity method investees				212,400	212,400		212,400		223,600
Total liabilities of equity method investees				$ 41,700	$ 41,700		41,700		37,900
Net losses of equity method investees							$ 48,600		$ 69,400
Pharmsynthez
Schedule of Equity Method Investments [Line Items]
Equity method investments (as a percent)				9.00%	9.00%		9.00%
Cocrystal
Schedule of Equity Method Investments [Line Items]
Equity method investments (as a percent)				3.00%	3.00%		3.00%
Number of shares into which warrants may be converted (in shares)				33,000	33,000		33,000
Non-Invasive Monitoring Systems, Inc.
Schedule of Equity Method Investments [Line Items]
Equity method investments (as a percent)				1.00%	1.00%		1.00%
Neovasc
Schedule of Equity Method Investments [Line Items]
Equity method investments (as a percent)				1.00%	1.00%		1.00%
BioCardia, Inc.
Schedule of Equity Method Investments [Line Items]
Equity method investments (as a percent)				1.00%	1.00%		1.00%
Equity security investments (as a percent)				1.00%	1.00%		1.00%
Number of shares into which warrants may be converted (in shares)				47,000	47,000		47,000		47,000
Xenetic Biosciences, Inc.
Schedule of Equity Method Investments [Line Items]
Equity method investments (as a percent)				3.00%	3.00%		3.00%
LeaderMed
Schedule of Equity Method Investments [Line Items]
Stock ownership (as a percent)							47.00%
Sema4
Schedule of Equity Method Investments [Line Items]
Net losses for fair value changes in investment		$ 71,200
Phio Pharmaceuticals
Schedule of Equity Method Investments [Line Items]
Equity security investments (as a percent)				0.01%	0.01%		0.01%
VBI Vaccines Inc
Schedule of Equity Method Investments [Line Items]
Equity security investments (as a percent)				1.00%	1.00%		1.00%
ChromaDex
Schedule of Equity Method Investments [Line Items]
Equity security investments (as a percent)				0.10%	0.10%		0.10%
Eloxx Pharmaceuticals
Schedule of Equity Method Investments [Line Items]
Equity security investments (as a percent)				1.00%	1.00%		1.00%
CAMP4
Schedule of Equity Method Investments [Line Items]
Equity security investments (as a percent)				2.00%	2.00%		2.00%
HealthSnap
Schedule of Equity Method Investments [Line Items]
Equity security investments (as a percent)				7.00%	7.00%		7.00%
InCellDx, Inc
Schedule of Equity Method Investments [Line Items]
Equity method investments (as a percent)				29.00%	29.00%		29.00%
Number of shares into which warrants may be converted (in shares)				700,000	700,000		700,000
Zebra
Schedule of Equity Method Investments [Line Items]
Stock ownership (as a percent)							29.00%
Zebra | Variable Interest Entity, Not Primary Beneficiary
Schedule of Equity Method Investments [Line Items]
Equity method investments (as a percent)				29.00%	29.00%		29.00%
Series A Preferred Stock | Zebra | Variable Interest Entity, Not Primary Beneficiary
Schedule of Equity Method Investments [Line Items]
Investment owned (in shares)				1,260,000	1,260,000		1,260,000
Restricted Stock | Zebra | Variable Interest Entity, Not Primary Beneficiary
Schedule of Equity Method Investments [Line Items]
Shares received as a gift (in shares)							900,000
Common Stock
Schedule of Equity Method Investments [Line Items]
Stock price (in dollars per share)	$ 2.44
Sema4 | Sema4
Schedule of Equity Method Investments [Line Items]
Equity method investments (as a percent)				21.20%	21.20%		21.20%
Sema4 | Common Class A
Schedule of Equity Method Investments [Line Items]
Investment owned (in shares)				80,000,000	80,000,000		80,000,000
ModeX Therapeutics Inc
Schedule of Equity Method Investments [Line Items]
Total aggregate consideration	$ 300,000
Total purchase price	221,662
Vested equity awards	2,300
Revenue				$ 0
Net income (loss)				$ 1,100
ModeX Therapeutics Inc | Common Stock
Schedule of Equity Method Investments [Line Items]
Value of consideration shares	$ 219,400
Stock price (in dollars per share)	$ 2.44
Detect Genomix | Sema4
Schedule of Equity Method Investments [Line Items]
Total aggregate consideration		447,000
Payments to acquire business		$ 150,000
Outstanding shares held (as a percent)		5.00%